Bispecific Antibody Therapy
Cross-source consensus on Bispecific Antibody Therapy from 1 sources and 3 claims.
1 sources · 3 claims
Uses
Evidence quality
Other
Highlighted claims
- Bispecific antibody inclusion depends on institutional, regulatory, contractual, and sponsor requirements. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
- CLARITY includes infection outcomes after bispecific antibody therapy in adults with lymphoproliferative neoplasms. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
- Among lymphoma patients treated with bispecific antibodies, the aetiology of many severe infections has not been reported. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol